TR201905447T4 - Yeni mhc bağımsız tümörle ilişkili antijenler. - Google Patents

Yeni mhc bağımsız tümörle ilişkili antijenler. Download PDF

Info

Publication number
TR201905447T4
TR201905447T4 TR2019/05447T TR201905447T TR201905447T4 TR 201905447 T4 TR201905447 T4 TR 201905447T4 TR 2019/05447 T TR2019/05447 T TR 2019/05447T TR 201905447 T TR201905447 T TR 201905447T TR 201905447 T4 TR201905447 T4 TR 201905447T4
Authority
TR
Turkey
Prior art keywords
antigens
cells
cell
tumor associated
nucleic acids
Prior art date
Application number
TR2019/05447T
Other languages
English (en)
Inventor
Schadendorf Dirk
Paschen Anette
Lübcke Silke
Fatho Martina
Eberts Daniela
Echchannaoui Hakim
Lennerz Volker
Wölfel Catherine
Wölfel Thomas
Original Assignee
Biontech Rna Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Rna Pharmaceuticals Gmbh filed Critical Biontech Rna Pharmaceuticals Gmbh
Publication of TR201905447T4 publication Critical patent/TR201905447T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001118—Receptors for colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y503/00—Intramolecular oxidoreductases (5.3)
    • C12Y503/03—Intramolecular oxidoreductases (5.3) transposing C=C bonds (5.3.3)
    • C12Y503/03012—L-Dopachrome isomerase (5.3.3.12)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

Mevcut buluş, MHC aracılığıyla bir CD8 pozitif T hücre yanıtı prezentasyonundan bağımsız olarak ortaya çıkan yeni tümörle ilişkili antijenler ile ilgilidir. GM-CSF Reseptörü alfa zincirinin (CSF2RA) ve Tirozinaz ilişkili proteinin (2) (TRP-2), HLA I negatif melanom hücrelerinin yüzeyindeki proteinleri saptayabilecek CD8 pozitif T hücre klonlarının hedefleri olduğu bulundu. Dolayısıyla, buluş ilaç olarak, örneğin, bir tümör hastalığının tedavisi, teşhisi ve önlenmesi için kullanıma yönelik yeni antijenlerin proteinlerini, protein fragmanlarını ve polipeptidlerini sağlar. Ayrıca, buluşun antijenlerini eksprese eden nükleik asitler, buluşun antijenlerine özel, buluşun antijenlerine karşı reaktif olan ve buluşun T hücresi reseptörlerini eksprese eden T hücresi reseptörü zincirleri ve izole edilmiş T hücreleri gibi bağlayıcı maddeler sağlanmaktadır. Buluş ayrıca, buluşa uygun olarak antijenler, nükleik asitler, bağlayıcı maddeler veya T hücreleri içeren farmasötik bileşimleri, özellikle aşı bileşimleri ve bir MHC bağımsız şeklinde buluşun antijenlerine özellikle reaktif T hücrelerini oluşturma yöntemleri ile ilgilidir.
TR2019/05447T 2012-12-14 2013-12-16 Yeni mhc bağımsız tümörle ilişkili antijenler. TR201905447T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12197289 2012-12-14

Publications (1)

Publication Number Publication Date
TR201905447T4 true TR201905447T4 (tr) 2019-05-21

Family

ID=47355928

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/05447T TR201905447T4 (tr) 2012-12-14 2013-12-16 Yeni mhc bağımsız tümörle ilişkili antijenler.

Country Status (13)

Country Link
US (2) US9861688B2 (tr)
EP (1) EP2932264B1 (tr)
JP (1) JP6475166B2 (tr)
AU (2) AU2013357239B2 (tr)
CA (2) CA2894966C (tr)
DK (1) DK2932264T3 (tr)
ES (1) ES2721159T3 (tr)
HU (1) HUE042967T2 (tr)
PL (1) PL2932264T3 (tr)
PT (1) PT2932264T (tr)
SI (1) SI2932264T1 (tr)
TR (1) TR201905447T4 (tr)
WO (1) WO2014091034A1 (tr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3607974A1 (en) 2013-03-15 2020-02-12 The Trustees of The University of Pennsylvania Cancer vaccines and methods of treatment using the same
EP3730515B1 (en) 2015-02-16 2023-07-26 The Trustees of the University of Pennsylvania A fully-human t cell receptor specific for the 369-377 epitope derived from the her2/neu (erbb2) receptor protein
CA3090791A1 (en) * 2018-02-11 2019-08-15 Memorial Sloan-Kettering Cancer Center Non-hla restricted t cell receptors and uses thereof
CA3196544A1 (en) * 2020-10-27 2022-05-05 Ying Q. LIN Recombinant t-cell receptors that bind the ny-eso-1 and/or lage-1a cancer antigens
WO2022155375A2 (en) * 2021-01-13 2022-07-21 Washington University MHC-INDEPENDENT TCRs AND METHODS OF MAKING AND USING SAME
US20230057987A1 (en) * 2021-07-27 2023-02-23 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding ct45

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3267966B2 (ja) * 1989-08-11 2002-03-25 アムラド・コーポレイション・リミテッド 顆粒球―マクロファージコロニー刺激因子受容体およびその誘導体における改良
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
AU2002243444A1 (en) 2000-10-31 2002-06-24 Diadexus, Inc. Compositions and methods relating to colon specific genes and proteins
CN103641916A (zh) 2006-03-27 2014-03-19 医学免疫有限公司 Gm-csf受体结合元件
WO2007131092A2 (en) 2006-05-03 2007-11-15 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
WO2008039818A2 (en) * 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
US8489339B2 (en) * 2006-11-03 2013-07-16 St. Vincent's Institute Of Medical Research Crystalline composition of GM-CSF/GM-CSFR
WO2010088160A1 (en) 2009-01-28 2010-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
WO2011029126A1 (en) * 2009-09-14 2011-03-17 Walter And Eliza Hall Institute Of Medical Research Methods and reagents for producing antibodies against autoantigens
ME02810B (me) * 2010-09-20 2018-01-20 Biontech Cell & Gene Therapies Gmbh Antigen-specifični t ćelijski receptori i t ćelijski epitopi

Also Published As

Publication number Publication date
EP2932264A1 (en) 2015-10-21
EP2932264B1 (en) 2019-01-30
HUE042967T2 (hu) 2019-07-29
US20180099033A1 (en) 2018-04-12
WO2014091034A1 (en) 2014-06-19
US9861688B2 (en) 2018-01-09
AU2019236675A1 (en) 2019-10-17
AU2013357239B2 (en) 2019-10-17
DK2932264T3 (da) 2019-05-06
AU2013357239A1 (en) 2015-06-18
US20150313978A1 (en) 2015-11-05
AU2019236675B2 (en) 2022-02-24
PL2932264T3 (pl) 2019-09-30
PT2932264T (pt) 2019-05-21
CA3108192A1 (en) 2014-06-19
US10987413B2 (en) 2021-04-27
SI2932264T1 (sl) 2019-05-31
ES2721159T3 (es) 2019-07-29
JP2016501268A (ja) 2016-01-18
CA2894966A1 (en) 2014-06-19
JP6475166B2 (ja) 2019-02-27
CA2894966C (en) 2021-03-30

Similar Documents

Publication Publication Date Title
AU2019283892A1 (en) Anti-human papillomavirus 16 E7 T cell receptors
TR201905447T4 (tr) Yeni mhc bağımsız tümörle ilişkili antijenler.
MX2019009641A (es) Receptores de la celula t que reconocen mhc de mage-a3 de clase ii-restringida.
MX2020003117A (es) Receptores de celulas t restringidas a hla de clase ii contra ras mutado.
MX2020005765A (es) Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado.
CL2021002997A1 (es) Construcción de reconocimiento de antígeno y su uso para el tratamiento de enfermedades proliferativas y para la detección in vitro de un cáncer (divisional de la solicitud 201901535)
BR112019008560A2 (pt) célula artificial que apresenta antígeno, método para expandir linfócitos infiltrantes de tumor, para tratar um câncer com uma população de linfócitos infiltrantes de tumor e para avaliar a potência de linfócitos infiltrantes de tumor, kit, população de linfócitos infiltrantes de tumor, e, combinação
EA201791150A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака
EA201792484A1 (ru) Новые клеточные эпитопы и комбинации клеточных эпитопов для применения в иммунотерапии миеломы и других видов рака
EA201792044A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака
CY1121466T1 (el) Αντισωματα εναντι προσδεματων υποδοχεα β1 βραδυκινινης
BR112014008694A2 (pt) moléculas de ácido nucleico policistrônico recombinante
PH12018501335A1 (en) Novel generation of antigen-specific tcrs
MX2019008346A (es) Receptores de celulas t que se unen a ny-eso-1 y metodos de uso de estos.
CL2021001794A1 (es) Péptido, ácido nucleico, célula, composición farmacéutica, linfocito t activado, agente de unión aislado, y tcr, para su uso en inmunoterapia contra el cáncer; y métodos para producirlos (divisional de la solicitud no. 201600227)
MX364370B (es) Vacunas contra el cancer personalizadas y terapias de celulas inmunes adoptivas.
TR201908404T4 (tr) İşlenmiş yüksek afinite insan t hücresi reseptörleri.
EA202090757A1 (ru) T-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, РАСПОЗНАЮЩИЕ МУТАНТНЫЙ p53
CL2017002407A1 (es) Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores
MX2012008657A (es) Peptidos melk modificados y vacunas que contienen los mismos.
BR112013013158B1 (pt) composições farmacêutica para uso no tratamento de câncer, métodos in vitro para induzir célula apresentadora de antígeno, bem como vetor, e uso
TR201901466T4 (tr) Opti̇mi̇ze edi̇lmi̇ş feli̇n lösemi̇ vi̇rüsü zarf geni̇ni̇ i̇çeren rekombi̇nant feli̇n lösemi̇ vi̇rüsü
WO2016077525A3 (en) Human anti-thyroglobulin t cell receptors
MX365656B (es) Nuevas vacunas contra multiples subtipos del virus del dengue.
AR121812A2 (es) Péptido, vector de expresión, célula huésped, linfocito t activado, anticuerpo, receptor de células t, composición farmacéutica, kit y métodos relacionados